Equities researchers at Leerink Partners started coverage on shares of Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) in a report released on Tuesday, MarketBeat.com reports. The brokerage set an “outperform” rating and a $44.00 price target on the stock. Leerink Partners’ price target would suggest a potential upside of 73.36% from the stock’s previous close.
ORKA has been the topic of a number of other reports. TD Cowen began coverage on shares of Oruka Therapeutics in a report on Monday. They set a “buy” rating on the stock. Wedbush began coverage on shares of Oruka Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 target price on the stock. Jefferies Financial Group began coverage on shares of Oruka Therapeutics in a report on Friday, September 13th. They set a “buy” rating and a $40.00 target price on the stock. Finally, Lifesci Capital began coverage on shares of Oruka Therapeutics in a report on Monday. They set an “outperform” rating and a $41.00 target price on the stock. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $41.25.
View Our Latest Stock Report on Oruka Therapeutics
Oruka Therapeutics Price Performance
Oruka Therapeutics Company Profile
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.
Read More
- Five stocks we like better than Oruka Therapeutics
- Learn Technical Analysis Skills to Master the Stock Market
- How Much Can You Make in Stocks in One Month?
- What is Short Interest? How to Use It
- This Is the Top Large-Cap Stock Insiders Are Buying
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.